SPECIFIC PHARMA A/S: Financial statements 2020
CVR: 33161395
Source: annual report 2020, Danish Business Authority
01/02/2019 – 31/01/2020
SPECIFIC PHARMA A/S (CVR 33161395) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 128,248,000 and a net result of DKK 8,237,000 compared with DKK 8,914,000 the year before. That is a decrease of 12.4% compared with the year before. The profit margin was 6.4%. Equity in the 2020 report amounted to DKK 80,199,000. The solvency ratio was 84.1%. The company had 16 employees in the financial year.
- Revenue
- DKK 128,248,000
- Gross Profit
- DKK 27,006,000
- Profit/Loss
- DKK 8,237,000
- Equity
- DKK 80,199,000
- Total Assets
- DKK 95,307,000
- Employees
- 16
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 128.2 mio. | 27 mio. | 8.2 mio. | 80.2 mio. | 16 |
| 2019 | 146.4 mio. | 25.3 mio. | 8.9 mio. | 78.6 mio. | 15 |
| 2018 | 145.7 mio. | 29.7 mio. | 14.8 mio. | 69.7 mio. | 12 |
| 2017 | 142.4 mio. | 41.9 mio. | 26.2 mio. | 74.6 mio. | 8 |
| 2016 | 141.1 mio. | - | 20.2 mio. | 63.5 mio. | 8 |
Official annual report
How creditworthy is SPECIFIC PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of December 4, 2020, Pia Rask Stewart has joined the board of directors of SPECIFIC PHARMA A/S.
As of December 4, 2020, Per Bornhøft Hansen has left the board of directors of SPECIFIC PHARMA A/S.
About SPECIFIC PHARMA A/S
SPECIFIC PHARMA A/S is a Danish company of the type Aktieselskab based in København SV, founded in 2010. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Uffe Kåre Jensen. The board consists of Kristine Sakstrup Haag (chair), Henrik Kaastrup, Kasper Casparij Yde and Ken Rasmussen. The company is owned by NOMECO A/S. The company has 24 employees (2018). In 2026, the company reported revenue of DKK 157,797,000 and a net result of DKK 15,192,000 compared with DKK 29,239,000 the year before. Equity in the 2026 report amounted to DKK 98,645,000.